Join IPM at HIV R4P 2014!

Join IPM in Cape Town 28-31 Oct. for the inaugural HIV Research for Prevention (R4P) Conference and get the scoop on the latest research advances in microbicides, MPTs and other products in development that could help turn the tide of the HIV/AIDS epidemic.

Find us at the oral and poster presentations listed below, where IPM and its partners will share updates on our clinical trials and product pipeline to address women’s sexual and reproductive health needs.

Not attending R4P? Follow us on Twitter at @IPMicrobicides to keep up with news and quotes that catch our eye.

Oral Abstracts

Tues., 28 Oct.

OA03.04.  A Combination Vaginal Ring Releasing Dapivirine and Darunavir (IPM-supported)
11:45-12:00, Level 1, Auditorium 2
Session: Animal model studies of microbicides

OA09.02.  Community Engagement in a Volatile Community Post-marikana for a Phase III Microbicide Ring Trial
13:45-14:00, Level 2, Meeting Room 2.40
Session: Engaging, recruiting and retaining trial participants

Weds., 29 Oct.

Oral Abstract Session: PrEP and Microbicide Adherence in Women
11:00-12:30, Level 2, Roof Terrace Room
Session Co-chair: Zeda Rosenberg, CEO, IPM

OA13.01.  Defining Pharmacokinetic and Pharmacodynamic linkages between Genital Tissue and Lumen Compartments
11:00-11:15, Level 1, Auditorium 2
Session: ARV exposure and efficacy in the genital tract

OA13.06.  Population Pharmacokinetic Modelling of Dapivirine
12:15-12:30, Level 1, Auditorium 2
Session: ARV exposure and efficacy in the genital tract

Thurs., 30 Oct.

OA22.02.  Pharmacodynamic Activity in Ectocervical and Colonic Tissue of Dapivirine, Maraviroc, and Combination Topical Gels for HIV Prevention
11:15-11:30, Level 1, Meeting Room 1.60
Session: Cell and tissue models of ARVs for prevention

OA26.03.  Development of Reservoir Vaginal Rings Containing Dapivirine or Hormonal Contraceptive Steroids
14:00-14:15, Level 1, Auditorium 1
Session: Microbicides and multipurpose prevention technologies
Session Co-chair: Jeremy Nuttall, Senior Director of Pre-Clinical Sciences & Product Development, IPM

Poster Presentations

Weds., 29 Oct.

Poster Session (Themes P01-P26)
10:00-11:00 and 17:00-18:30, Level 0, Hall 2

P05: Family planning

  • P05.05. Contraceptive Preference Among HIV High Risk Women Pre-Screened for a Phase III Vaginal Microbicide Trial in South-Western Uganda

P09: HIV testing and counseling

  • P09.18 LB. Does Culture Affect Counselling in HIV Prevention Research?

P14: MPT development

  • P14.01. Drug-Drug Interaction Studies Investigating the Impact of Levonorgestrel on Antiviral Potency of Dapivirine
  • P14.03. Formulation Development of a Combination Silicone Elastomer Ring for Vaginal Delivery of Dapivirine and Levonorgestrel
  • P14.04. Matrix Vaginal Ring Formulations That Maintain Target In-Vitro Release Rates of Dapivirine and Levonorgestrel (Alone or in Combination) over 90 days
  • P14.05. In Vitro Design and Drug Delivery of Combination Dapivirine and Contraceptive Hormone Ethylene Vinyl Acetate (EVA) Vaginal Ring Prototypes
  • P14.06. Evaluation of the Factors Contributing to Levonorgestrel Binding in Addition Cure Silicone Elastomer Vaginal Rings
  • P14.07. Thermal Properties and Eutectic Behaviour of Dapivirine in Combination with Steroid Hormones and Other Antiretrovirals
  • P14.08. Selection of a Hormonal Contraceptive Agent for Inclusion with Dapivirine in a Silicone Elastomer Vaginal Ring
  • P14.10. Multipurpose Prevention of HIV and Pregnancy: Perspectives of Users, Providers and Community Advisors in Zimbabwe and Malawi

P15: Novel formulations, agents and microbicides

  • P15.09. Drug-Drug Interaction between the Dapivirine Vaginal Ring (RING-004) and Miconazole Nitrate Vaginal Capsule (GYNO-DAKTARIN®)
  • P15.14. Development of a Temperature-Recording Vaginal Ring for Monitoring User Adherence (IPM-supported)
  • P15.22. Fourteen-day Safety of Daily Vaginal Administration of Dapivirine-loaded Nanoparticles in a Mouse Model (IPM-supported)

P18: Preclinical evaluation of vaginal films and gels

  • P18.01. Characterization of a Dapivirine Impurity Found in Dapivirine Gel Product During Storage 
  • P18.05. Comparative Pharmacokinetics of DS003, a gp120 Binder and Candidate Microbicide in Rats, Rabbits and Dogs
  • P18.06. Dapivirine and Tenofovir Vaginal Films and Gels: Macaque Pharmacokinetics (IPM-supported)

P19: PrEP implementation

  • P19.05. Community Engagement and Male Involvement to Optimize Ring Adherence for Women Participants on a Phase III Microbicide Ring Trial

P21: Product acceptability and adherence

  • P21.02. Adherence Improvement Innovations to Enhance Protocol Compliance and Vaginal Ring Adherence in a Phase III HIV Prevention Study in KwaZulu-Natal

P23: Retention and adherence in trials

  • P23.04. Implementation of Tools to Optimize Protocol Compliance at the Madibeng Centre for Research

Thurs., 30 Oct.

Poster Session (Themes P27-P53)
10:00-11:00 and 17:00-18:30, Level 0, Hall 2

P43: Policy, advocacy and modeling

  • P43.08. Use of a Mathematical Model to Predict Dissolution Profiles of Dapivirine Vaginal Rings

P44: Preclinical Evaluation of Biomedical Agents in Animal Models Tissues Explants

  • P44.03. Preventing Drug Resistant HIV Infection in Colonic Tissue Using Tenofovir and Maraviroc Combination Topical Rectal Gels

P49: STIs

  • P49.11. Burden of Sexually Transmitted Infections Among High Risk Women Screened for a Phase III Microbicide Trial in Southwestern Uganda      

P53: Vaginal rings: Baseline characteristics, impact on condoms and flora

  • P53.01. Male Condom Functionality in the Presence of a Vaginal Ring
  • P53.02. Baseline Characteristics of HIV-Negative Women Enrolled into The Ring Study – a Clinical Trial of the Dapivirine Vaginal Ring for HIV-1 Prevention
  • P53.04. Effects of a Vaginal Ring Containing Maraviroc and or Dapivirine Worn for 28 Days on the Vaginal Microflora (IPM-supported)